指南与共识脑血管病

双联与单联抗血小板治疗用于卒中二级预防的获益与风险

Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack.
指南 / 共识 · Stroke · 2021-05-24

该系统综述纳入3项短疗程和2项长疗程随机对照试验,评估双联抗血小板治疗(DAPT)对比单联抗血小板治疗(SAPT)用于缺血性卒中或短暂性脑缺血发作(TIA)二级预防的获益与风险。短疗程DAPT(≤90天)降低90天复发性缺血性卒中风险(汇总RR 0.68,95%CI 0.55-0.83),未显著增加大出血;长疗程DAPT(>90天)未显著减少复发性缺血性卒中(汇总RR 0.89,95%CI 0.79-1.02),但增加大出血风险(汇总RR 2.42,95%CI 1.37-4.30)。

要点

  • 轻型卒中或高危TIA后早期启动DAPT且疗程≤90天可降低复发性缺血性卒中风险。
  • 短疗程DAPT未显著增加大出血风险(汇总RR 1.88,95%CI 0.93-3.83)。
  • 长疗程DAPT(>90天)未显著减少复发性缺血性卒中,但显著增加大出血风险。

核心结论

  • 轻型卒中或高危TIA后早期启动DAPT且疗程<90天,预防复发性缺血性卒中优于SAPT。
  • 长疗程且卒中或TIA后较晚启动DAPT,预防缺血性卒中不优于SAPT且增加出血风险。

研究设计与样本

  • 美国心脏协会/美国卒中协会召集证据审查委员会进行系统综述和荟萃分析。
  • 共纳入3项短疗程(≤90天)和2项长疗程(>90天)随机对照试验;短疗程试验主要纳入轻型卒中或高危TIA患者;长疗程试验平均治疗时长18-40个月。

主要发现

  • 短疗程试验中,DAPT对比SAPT的90天复发性缺血性卒中汇总RR为0.68(95%CI 0.55-0.83),I²=37.1%。
  • 短疗程试验中,DAPT对比SAPT的大出血汇总RR为1.88(95%CI 0.93-3.83),I²=8.9%,无显著增加。
  • 长疗程试验中,DAPT对比SAPT的复发性缺血性卒中汇总RR为0.89(95%CI 0.79-1.02),I²=1.4%,无显著减少。
  • 长疗程试验中,DAPT对比SAPT的大出血汇总RR为2.42(95%CI 1.37-4.30),I²=75.5%,风险显著增加。

临床怎么用

  • 对轻型卒中或高危TIA患者,可考虑早期启动DAPT并限制疗程≤90天以降低复发风险。
  • 避免在卒中或TIA后较晚启动长疗程DAPT,因其不显著减少缺血性卒中且增加大出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) after ischemic stroke or transient ischemic attack may reduce recurrent stroke but also increase severe bleeding compared with single antiplatelet therapy (SAPT). The American Heart Association/American Stroke Association convened an evidence review committee to perform a systematic review and meta-analysis of the benefits and risks of DAPT compared with SAPT for secondary ischemic stroke prevention. METHODS: The Medline, Embase, and Cochrane databases were searched on December 5, 2019, to identify phase III or IV randomized controlled trials (n≥100) from December 1999 to December 2019. We calculated unadjusted relative risks (RRs) and performed meta-analyses of studies based on the duration of treatment (short [≤90 days] versus long [>90 days]). RESULTS: Three short-duration randomized controlled trials were identified that enrolled mostly patients with minor stroke or high risk transient ischemic attack. In these trials, DAPT, compared with SAPT, was associated with a lower 90-day risk of recurrent ischemic stroke (pooled RR, 0.68 [95% CI, 0.55-0.83], I 2=37.1%). There was no significant increase in major bleeding with DAPT in short-duration trials (pooled RR, 1.88 [95% CI, 0.93-3.83], I 2=8.9%). In 2 long-duration treatment randomized controlled trials (mean treatment duration, 18-40 months), DAPT was not associated with a significant reduction in recurrent ischemic stroke (pooled RR, 0.89 [95% CI, 0.79-1.02], I 2=1.4%), but was associated with a higher risk of major bleeding (pooled RR, 2.42 [95% CI, 1.37-4.30], I 2=75.5%). CONCLUSIONS: DAPT was more effective than SAPT for prevention of secondary ischemic stroke when initiated early after the onset of minor stroke/high-risk transient ischemic attack and treatment duration was <90 days. However, when the treatment duration was longer and initiated later after stroke or transient ischemic attack onset, DAPT was not more effective than SAPT for ischemic stroke prevention and it increased the risk of bleeding.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Brown DL, Levine DA, Albright K, et al. Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021. PMID: 34024115. doi:10.1161/STR.0000000000000377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。